First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia

Wolf, Timo; Rickerts, Volker; Staszewski, Schlomo; Kriener, Susanne; Waßmann, Barbara; Bug, G.; Bickel, M; Gute, Peter; Brodt, Hans-Reinhard; Martin, Hans

doi:10.3324/haematol.11394

Cited by 29 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,5 Promising outcomes with non-malignant disease, and others using reduced-intensity conditioning have recently been reported. [6][7][8][9] Of particular interest is a recent case report describing allogeneic transplantation as dual therapy of AML and HIV. 10 In the reported case, a patient with newly diagnosed AML with normal cytogenetics and a 10-year history of HIV on HAART with no ADIs received as first-line therapy an allogeneic transplant from a CCR5 delta32/ delta32 HLA-matched unrelated donor.…”

Section: Resultsmentioning

confidence: 99%

Allo-SCT for hematological malignancies in the setting of HIV

Polizzotto

Skinner

Cole‐Sinclair

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Allo-SCT for hematological malignancies in the setting of HIV

Polizzotto

Skinner

Cole‐Sinclair

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Other investigators have published successful alloHCT transplant data, including evidence of effective virological control while on cART post-alloHCT. 56,57 The largest prospective trial to date is the BMT CTN 0903/AMC 080 trial. In this multi-institutional trial, 17 patients underwent either reduced-intensity (9) or fully ablative (8) alloHCT.…”

Section: Autologous Hematopoietice Cell Transplantation (Ahct) For Himentioning

confidence: 99%

“…The bulk of current data are based on single-institution, retrospective studies with small patient numbers. [52][53][54][55][56][57][58] In a recent retrospective publication, 5 patients with hematological malignancies underwent alloHCT from either sibling (2) or unrelated donors (3) at a single institution between 2010 and 2016. 59 All patients engrafted within 17 days with no TRM.…”

Section: Autologous Hematopoietice Cell Transplantation (Ahct) For Himentioning

confidence: 99%

How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation

Alvarnas

Zaia

Forman

2017

Blood

View full text Add to dashboard Cite

Hematopoietic cell transplantation (HCT) has now been shown to be safe and effective for selected HIV-infected patients with hematological malignancies. Autologous HCT is now the standard of care for patients with HIV-related lymphomas who otherwise meet standard transplant criteria. Limited data also support use of allogeneic HCT (alloHCT) in selected HIV-infected patients who meet standard transplant criteria. We recommend enrolling patients in clinical trials that offer access to CCR5Δ32 homozygous donors, if available. HIV-infected patients requiring HCT may also be considered for participation in trials evaluating the activity of gene-modified hematopoietic stem cells in conferring resistance to HIV infection. To be considered for HCT, patients must have HIV infection that is responsive to combination antiretroviral therapy (cART). Careful planning for the peri-HCT management of the cART can avoid risk of significant drug interactions and development of cART-resistant HIV. In general, we recommend against the use of boosted proteasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitors (without cobicistat). After HCT, patients must be closely monitored for development of opportunistic infections (OI), such as cytomegalovirus. Prevention of OI should include prophylactic and pre-emptive antimicrobials.

show abstract

“…In general, allotransplant experiences in the setting of HIV for hematological disorders are limited to some small reports 15 and only one single successful experience is described in the specific context of SAA. 5 Drug interactions with anti-retroviral therapy, comorbidities and co-infections in HIV-infected patients are major issues that make more difficult these kinds of transplants.…”

mentioning

confidence: 99%

“…Although hematological abnormalities are frequent in patients infected with HIV 3 and may have a complex origin, there have been only anecdotal case reports of SAA in the setting of HIV infection. 4,5 Advances in hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have improved survival in SAA and at least 80% of patients are alive at 5 years post diagnosis. 6 Nevertheless, the management of SAA in the setting of HIV infection remains a challenge.…”

mentioning

confidence: 99%